Clinical Trial Detail

NCT ID NCT03295227
Title Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

thymic carcinoma

thymoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.